News | February 27, 2025
Zydus Lifesciences to launch protection against new strain of influenza virus
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
The inspection was carried out from January 28 to February 1, 2025
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Subscribe To Our Newsletter & Stay Updated
